8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 23, 2015

LPATH, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-35706	16-1630142
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4025 Sorrento Valley Blvd.
San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)

(858) 678-0800

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01Other Events.

On March 23, 2015, Lpath, Inc. (the “Company”) issued a press release announcing that it will host a webcast and conference call on Tuesday, March 24, 2015, beginning at 4:30 p.m. Eastern Standard Time to update investors on the progress of Lpath’s programs. To listen to the live webcast, please visit the “Investor Calendar of Events” section of the Company’s corporate website at www.Lpath.com.  A webcast replay will be available shortly after the call at the same web address. To participate by telephone, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international) or 1-855-669-9657 (Canada).  A telephone replay will be available shortly afterwards by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or 855-669-9658 (Canada), using access code 10056823.

A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.	Description
99.1	Press Release, dated March 23, 2015.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LPATH, INC.
Dated: March 23, 2015	By:	/s/ Gary J.G. Atkinson
		Name: Gary J.G. Atkinson
		Title: Senior Vice President and Chief Financial Officer

3

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated March 23, 2015.

4

EX-99.1

Exhibit 99.1

Lpath to Hold Investor Update Conference Call

SAN DIEGO, March 23, 2015 — Lpath, Inc. (NASDAQ: LPTN), a leader in the discovery and development of lipid-targeted therapeutics, today announced that the company will host a conference call and live webcast tomorrow, Tuesday, March 24, 2015 beginning at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to update investors on the progress of Lpath’s programs. To participate in the live call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international) or 1-855-669-9657 (Canada) and ask to join the Lpath conference call. A telephone replay will be available approximately one hour after the live call by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or 855-669-9658 (Canada), access code 10056823. A live webcast of the call can be accessed on the “Investor Calendar of Events” section of Lpath’s corporate website at www.Lpath.com. A webcast replay will be available shortly after the call at the same web address.

About Lpath

San Diego-based Lpath, Inc. (NASDAQ: LPTN) is the category leader in lipid-targeted therapeutics. The company’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, for neuropathic pain and an anti-leukotriene antibody, Altepan, which is being studied in models of inflammatory bowel disease, respiratory disease and inflammation. For more information, visit www.Lpath.com.

CONTACT:

Gary Atkinson

Chief Financial Officer

Lpath, Inc.

858-926-3202

gatkinson@lpath.com

PUBLIC RELATIONS CONTACT:

Canale Communications

Rachel Hutman

619-849-5384

rachel@canalecomm.com